Published On: Wed, Oct 19th, 2016

New Analyst Ratings On Impax Laboratories, Inc. (NASDAQ:IPXL)


Recently stock market analysts have updated their consensus ratings on shares of Impax Laboratories, Inc. (NASDAQ:IPXL).

Most recent broker ratings

09/27/2016 – Impax Laboratories, Inc. was upgraded to “neutral” by analysts at Goldman Sachs. They now have a USD 26 price target on the stock.

08/17/2016 – Impax Laboratories, Inc. had its “overweight” rating reiterated by analysts at Piper Jaffray. They now have a USD 32 price target on the stock.

08/15/2016 – Impax Laboratories, Inc. was upgraded to “outperform” by analysts at Northland Securities. They now have a USD 30 price target on the stock.

08/10/2016 – Impax Laboratories, Inc. had its “buy” rating reiterated by analysts at WallachBeth Capital. They now have a USD 30 price target on the stock.

08/10/2016 – Impax Laboratories, Inc. had its “sector perform” rating reiterated by analysts at RBC Capital. They now have a USD 30 price target on the stock.

08/10/2016 – Impax Laboratories, Inc. had its “market perform” rating reiterated by analysts at Leerink Swann. They now have a USD 24 price target on the stock.

06/28/2016 – BMO Capital Markets began new coverage on Impax Laboratories, Inc. giving the company a “market perform” rating. They now have a USD 30 price target on the stock.

06/21/2016 – Impax Laboratories, Inc. was upgraded to “neutral” by analysts at Bank of America Merrill Lynch.

06/21/2016 – Impax Laboratories, Inc. had its “hold” rating reiterated by analysts at Deutsche Bank. They now have a USD 31 price target on the stock.

04/13/2016 – Impax Laboratories, Inc. had its “buy” rating reiterated by analysts at BTIG Research. They now have a USD 48 price target on the stock.

02/23/2016 – Impax Laboratories, Inc. had its “sell” rating reiterated by analysts at UBS. They now have a USD 30 price target on the stock.

02/23/2016 – Impax Laboratories, Inc. had its “positive” rating reiterated by analysts at Susquehanna. They now have a USD 43 price target on the stock.

02/17/2016 – Impax Laboratories, Inc. was upgraded to “market perform” by analysts at Raymond James.

01/06/2016 – Impax Laboratories, Inc. had its “neutral” rating reiterated by analysts at JP Morgan. They now have a USD 47 price target on the stock.

11/25/2015 – Impax Laboratories, Inc. had its “neutral” rating reiterated by analysts at Nomura. They now have a USD 40 price target on the stock.

Impax Laboratories, Inc. has a 50 day moving average of 24.38 and a 200 day moving average of 29.14. The stock’s market capitalization is 1.57B, it has a 52-week low of 20.97 and a 52-week high of 45.00.

The share price of the company (NASDAQ:IPXL) was up +1.61% during the last trading session, with a high of 22.15 and the volume of Impax Laboratories, Inc. shares traded was 405378.

Impax Laboratories, Inc. is a specialty pharmaceutical company. The Company is engaged in the development, manufacture and marketing of bioequivalent pharmaceutical products (generics), as well as the development and marketing of branded products. Its segments include Impax Generics and Impax Specialty Pharma. The Impax Generics segment is focused on the development, manufacture, sale and distribution of its generic products, which are the pharmaceutical and therapeutic equivalents of brand-name drug products and are marketed under their established drug names. The Impax Specialty Pharma segment is engaged in the promotion, sale and distribution of various branded products, including its branded pharmaceutical product, Rytary, an extended release oral capsule formulation of carbidopa-levodopa for the treatment of Parkinson’s disease, post-encephalitic Parkinsonism and Parkinsonism, and Zomig (zolmitriptan) products, indicated for the treatment of migraine headaches.